These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 22871711)
1. Stealing fire: a retrospective survey of biotech patent claims in the wake of Mayo v. Prometheus. Haanes EJ; Cànaves JM Nat Biotechnol; 2012 Aug; 30(8):758-60. PubMed ID: 22871711 [No Abstract] [Full Text] [Related]
2. The impact of Myriad and Mayo: will advancements in the biological sciences be spurred or disincentivized? (Or was biotech patenting not complicated enough?). Gordon J Cold Spring Harb Perspect Med; 2014 Dec; 5(5):a020917. PubMed ID: 25502748 [TBL] [Abstract][Full Text] [Related]
15. Patent first, ask questions later: morality and biotechnology in patent law. Bagley MA William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677 [TBL] [Abstract][Full Text] [Related]
17. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech. Garber K Science; 2006 May; 312(5775):827. PubMed ID: 16690824 [No Abstract] [Full Text] [Related]
18. Intellectual property. Biotech feels a chill from changing U.S. patent rules. Servick K Science; 2014 Jul; 345(6192):14-5. PubMed ID: 24994626 [No Abstract] [Full Text] [Related]
19. Prometheus bound, but myriad loose ends: amid new legal battles over BRCA tests, technology may resolve what the courts have not. Nelson B Cancer Cytopathol; 2013 Oct; 121(10):535-6. PubMed ID: 24130100 [No Abstract] [Full Text] [Related]
20. Proposed changes to patent code loom over biotech industry. Coombs A Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010 [No Abstract] [Full Text] [Related] [Next] [New Search]